Pharmafile Logo
Pharmafocus logo
Advanced Search

Kymriah

Showing 12 posts of 27 posts found.

Novartis’ CAR T therapy Kymriah to become available on the NHS

September 5, 2018
Research and Development CAR T, CAR-T, Gilead, Kymriah, NHS, Novartis

Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was …

News
novartis_mit_us

Novartis to create 450 new jobs at Aargau site after Kymriah thumbs up

August 29, 2018
Research and Development CAR T, CAR-T, Jobs, Kymriah, Novartis

Swiss multinational Novartis is set to create up to 450 new jobs following the investment of 90 million Swiss Francs …

News
european_commission_web

Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies

August 28, 2018
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …

News
kymriah

CHMP recommends Novartis’ CAR-T therapy Kymriah for EU approval

July 5, 2018
Sales and Marketing CAR-T, CHMP, EMA, EU, Kymriah, Novartis, pharma

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Medicines Agency (EMA) approve Novartis’ CAR-T …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

May 4, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia

It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …

News
novartis_window

Novartis becomes first to gain second CAR T indication

May 2, 2018
Research and Development, Sales and Marketing Gilead, Kymriah, Novartis, Yescarta, biotech, drugs, pharma, pharmaceutical

Novartis has announced that its CAR T treatment, Kymriah, has successfully been given a second indication for the treatment of …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten

It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …

News
novartis_outside_1

Novartis’ CAR T therapy Kymriah scores accelerated approval in both Europe and US

January 17, 2018
Research and Development, Sales and Marketing CAR T, CAR-T, EMA, Europe, FDA, Kymriah, Novartis, US, pharma

Following up last year’s ground-breaking news that CAR T therapy Kymriah had become the first such treatment to be approved …

News

Novartis reveals the data behind its showdown with Gilead

November 1, 2017
Research and Development CAR-T, Gilead, Kymriah, Novartis, biotech, drugs, pharma, pharmaceutical

Only yesterday it was revealed that Novartis had applied to the FDA in the same indication that Gilead’s treatment is …

News
_97604447_kymriah-product-shot-8

CAR-T is bringing true precision to the fight against cancer

November 1, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Gilead, Kymriah, Novartis, Yescarta

Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …

Feature

Novartis submits second FDA application for CAR-T therapy Kymriah, this time in diffuse large B-cell lymphoma

October 31, 2017
Manufacturing and Production, Sales and Marketing CAR-T, Kymriah, Novartis

Following the “historic” FDA approval of the company’s CAR-T therapy Kymriah (tisagenlecleucel) in the treatment of paediatric and young adults …

News
novartis_hq_day

CAR-T treatment is given ‘historic’ first approval by FDA

August 31, 2017
Research and Development, Sales and Marketing CAR-T, Kymriah, Novartis, biotech, drugs, pharma, pharmaceutical

Novartis has received approval for its CAR-T treatment of paediatric and young adults with a form of acute lymphoblastic leukaemia …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024